Impedimed Ltd has released a press release.
IPD Submits FDA 510(k) Application for SOZO for Lymphoedema
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Impedimed
- L-Dex Recommended in Clinical Practice Guidelines
- SOZO obtains CE Mark for Heart Failure Patient Monitoring
- Macquarie University Commences Lymphoedema Study Using Sozo
- L-Dex Study - Significant Reduction in Clinical Lymphoedema
- March 2017 Quarter Results & Investor Conference Call
Later from Impedimed
- Appendix 4C - Quarter ended 30 June 2017
- First patient enrolled in SOZO CHF Trial at Scripps Health
- US FDA 510(k) Clearance Issued for SOZO with L-Dex
- Heart Failure 510(k) Application for SOZO Submitted to FDA
- Appendix 4E - year ended 30 June 2017
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed